Souhaitez-vous accéder aux communiqués récents ?

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD

Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient...

Pittsburgh, PA, March 27, 2026 (GLOBE NEWSWIRE) -- Ground was broken today for a second Fisher House supporting the VA Pittsburgh Healthcare System in Pittsburgh, Pennsylvania, increasing capacity...

Washington, D.C., March 27, 2026 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), the nation’s leading advocacy organization dedicated to ending colorectal cancer, hosted its 20th Annual...

Belleville, Illinois, March 27, 2026 (GLOBE NEWSWIRE) -- Allsup, a nationwide disability benefits advocate, and its Allsup Veterans Appeals℠ (AVA) are highlighting support for Vietnam veterans in...

SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an...

Silver Spring, MD, March 27, 2026 (GLOBE NEWSWIRE) -- The American Nurses Enterprise (ANE) today announced new findings from the INVEST Study, a national mixed-methods analysis designed to quantify...

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the...